{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:37:18Z","timestamp":1784979438115,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH115860"],"award-info":[{"award-number":["R01MH115860"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH121402"],"award-info":[{"award-number":["R01MH121402"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["R24OD018546"],"award-info":[{"award-number":["R24OD018546"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Developmental grant provided by the University of Nebraska Medical Center to Prasanta K Dash."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08499-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T14:26:11Z","timestamp":1752935171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-1292","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7339-8732","authenticated-orcid":false,"given":"Larisa Y.","family":"Poluektova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-0370","authenticated-orcid":false,"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-2359","authenticated-orcid":false,"given":"Prasanta K.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"8499_CR1","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/jac\/dkac056","volume":"77","author":"OT Bareng","year":"2022","unstructured":"Bareng, O. T. et al. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. J. Antimicrob. Chemother. 77, 1385\u20131395 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"8499_CR2","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.0800050105","volume":"105","author":"S Palmer","year":"2008","unstructured":"Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105, 3879\u20133884 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8499_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/COH.0000000000000287","volume":"11","author":"J Martinez-Picado","year":"2016","unstructured":"Martinez-Picado, J. & Deeks, S. G. Persistent HIV-1 replication during antiretroviral therapy. Curr. Opin. HIV AIDS 11, 417\u2013423 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"8499_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3851\/IMP2949","volume":"20","author":"MA Vandenhende","year":"2015","unstructured":"Vandenhende, M. A. et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir. Ther. 20, 655\u2013660 (2015).","journal-title":"Antivir. Ther."},{"key":"8499_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/QAD.0b013e32834490b1","volume":"25","author":"T Le","year":"2011","unstructured":"Le, T., Farrar, J. & Shikuma, C. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Aids 25, 871\u2013872 (2011). author reply 872-3.","journal-title":"Aids"},{"key":"8499_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.chom.2015.01.008","volume":"17","author":"MD Marsden","year":"2015","unstructured":"Marsden, M. D. & Zack, J. A. Double trouble: HIV latency and CTL escape. Cell Host Microbe 17, 141\u2013142 (2015).","journal-title":"Cell Host Microbe"},{"key":"8499_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","volume":"48","author":"A Bandera","year":"2019","unstructured":"Bandera, A. et al. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr. Opin. Pharm. 48, 24\u201332 (2019).","journal-title":"Curr. Opin. Pharm."},{"key":"8499_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","volume":"530","author":"R Lorenzo-Redondo","year":"2016","unstructured":"Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51\u201356 (2016).","journal-title":"Nature"},{"key":"8499_CR9","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/v6104095","volume":"6","author":"P Iyidogan","year":"2014","unstructured":"Iyidogan, P. & Anderson, K. S. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 6, 4095\u20134139 (2014).","journal-title":"Viruses"},{"key":"8499_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina, H. et al. Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 3, 2510 (2013).","journal-title":"Sci. Rep."},{"key":"8499_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14712598.2015.1036736","volume":"15","author":"S Saayman","year":"2015","unstructured":"Saayman, S. et al. The therapeutic application of CRISPR\/Cas9 technologies for HIV. Expert Opin. Biol. Ther. 15, 819\u2013830 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"8499_CR12","doi-asserted-by":"publisher","first-page":"102667","DOI":"10.1016\/j.ebiom.2020.102667","volume":"53","author":"PK Dash","year":"2020","unstructured":"Dash, P. K. et al. Pathways towards human immunodeficiency virus elimination. EBioMedicine 53, 102667 (2020).","journal-title":"EBioMedicine"},{"key":"8499_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10366-y","volume":"10","author":"PK Dash","year":"2019","unstructured":"Dash, P. K. et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat. Commun. 10, 2753 (2019).","journal-title":"Nat. Commun."},{"key":"8499_CR14","doi-asserted-by":"publisher","first-page":"e2217887120","DOI":"10.1073\/pnas.2217887120","volume":"120","author":"PK Dash","year":"2023","unstructured":"Dash, P. K. et al. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice. Proc. Natl Acad. Sci. USA 120, e2217887120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8499_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.chom.2019.08.003","volume":"26","author":"MA De Scheerder","year":"2019","unstructured":"De Scheerder, M. A. et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe 26, 347\u2013358.e7 (2019).","journal-title":"Cell Host Microbe"},{"key":"8499_CR16","doi-asserted-by":"crossref","unstructured":"Vibholm, L. K. et al. Characterization of intact proviruses in blood and lymph node from HIV-infected individuals undergoing analytical treatment interruption. J. Virol. 93, 1\u201311 (2019).","DOI":"10.1128\/JVI.01920-18"},{"key":"8499_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/QAD.0000000000001400","volume":"31","author":"A Winckelmann","year":"2017","unstructured":"Winckelmann, A. et al. Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. Aids 31, 771\u2013779 (2017).","journal-title":"Aids"},{"key":"8499_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nm.2316","volume":"17","author":"M Rolland","year":"2011","unstructured":"Rolland, M. et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17, 366\u2013371 (2011).","journal-title":"Nat. Med."},{"key":"8499_CR19","doi-asserted-by":"publisher","first-page":"113737","DOI":"10.1016\/j.jviromet.2019.113737","volume":"274","author":"L Hebberecht","year":"2019","unstructured":"Hebberecht, L. et al. Single genome sequencing of near full-length HIV-1 RNA using a limiting dilution approach. J. Virol. Methods 274, 113737 (2019).","journal-title":"J. Virol. Methods"},{"key":"8499_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","volume":"16","author":"PP Rose","year":"2000","unstructured":"Rose, P. P. & Korber, B. T. Detecting hypermutations in viral sequences with an emphasis on G -> A hypermutation. Bioinformatics 16, 400\u2013401 (2000).","journal-title":"Bioinformatics"},{"key":"8499_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58544-z","volume":"10","author":"ER Lee","year":"2020","unstructured":"Lee, E. R. et al. Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. Sci. Rep. 10, 1634 (2020).","journal-title":"Sci. Rep."},{"key":"8499_CR22","doi-asserted-by":"crossref","unstructured":"Parkin, N. T. et al. Multi-laboratory comparison of next-generation to Sanger-Based Sequencing for HIV-1 drug resistance genotyping. Viruses. 12, 1\u201313 (2020).","DOI":"10.3390\/v12070694"},{"key":"8499_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0395-4","volume":"15","author":"G Van Zyl","year":"2018","unstructured":"Van Zyl, G., Bale, M. J. & Kearney, M. F. HIV evolution and diversity in ART-treated patients. Retrovirology 15, 1\u201312 (2018).","journal-title":"Retrovirology"},{"key":"8499_CR24","first-page":"559","volume":"30","author":"AM Wensing","year":"2022","unstructured":"Wensing, A. M. et al. 2022 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 30, 559\u2013574 (2022).","journal-title":"Top. Antivir. Med."},{"key":"8499_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/bioinformatics\/btp134","volume":"25","author":"RJ Gifford","year":"2009","unstructured":"Gifford, R. J. et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25, 1197\u20131198 (2009).","journal-title":"Bioinformatics"},{"key":"8499_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.20980","volume":"30","author":"A Rohlin","year":"2009","unstructured":"Rohlin, A. et al. Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. Hum. Mutat. 30, 1012\u20131020 (2009).","journal-title":"Hum. Mutat."},{"key":"8499_CR27","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/jac\/dkx232","volume":"72","author":"EK Alidjinou","year":"2017","unstructured":"Alidjinou, E. K. et al. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients. J. Antimicrob. Chemother. 72, 2823\u20132830 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"8499_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03454-22","volume":"10","author":"V Novitsky","year":"2022","unstructured":"Novitsky, V. et al. Added value of next generation over sanger sequencing in Kenyan youth with extensive HIV-1 drug resistance. Microbiol Spectr. 10, e0345422 (2022).","journal-title":"Microbiol Spectr."},{"key":"8499_CR29","doi-asserted-by":"publisher","first-page":"104207","DOI":"10.1016\/j.jcv.2019.104207","volume":"121","author":"EK Alidjinou","year":"2019","unstructured":"Alidjinou, E. K. et al. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay. J. Clin. Virol. 121, 104207 (2019).","journal-title":"J. Clin. Virol."},{"key":"8499_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/mt.2016.24","volume":"24","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol. Ther. 24, 522\u2013526 (2016).","journal-title":"Mol. Ther."},{"key":"8499_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","volume":"15","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. CRISPR\/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep. 15, 481\u2013489 (2016).","journal-title":"Cell Rep."},{"key":"8499_CR32","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1128\/JVI.02010-06","volume":"81","author":"S Gorantla","year":"2007","unstructured":"Gorantla, S. et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB\/c-Rag2\u2212\/\u2212 \u03b3c\u2212\/\u2212 mice. J. Virol. 81, 2700\u20132712 (2007).","journal-title":"J. Virol."},{"key":"8499_CR33","doi-asserted-by":"publisher","first-page":"418920","DOI":"10.3389\/fimmu.2019.00340","volume":"10","author":"H Su","year":"2019","unstructured":"Su, H. et al. Immune activations and viral tissue compartmentalization during progressive HIV-1 infection of humanized mice. Front. Immunol. 10, 418920 (2019).","journal-title":"Front. Immunol."},{"key":"8499_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02885-x","volume":"9","author":"B Sillman","year":"2018","unstructured":"Sillman, B. et al. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. 9, 443 (2018).","journal-title":"Nat. Commun."},{"key":"8499_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nano.2015.09.009","volume":"12","author":"G Zhang","year":"2016","unstructured":"Zhang, G. et al. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomed.: Nanotechnol., Biol. Med. 12, 109\u2013122 (2016).","journal-title":"Nanomed.: Nanotechnol., Biol. Med."},{"key":"8499_CR36","doi-asserted-by":"publisher","unstructured":"Garcia-Vidal, E. et al. Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir. Antimicrob. Agents Chemother. 61, https:\/\/doi.org\/10.1128\/aac.01368-17, (2017).","DOI":"10.1128\/aac.01368-17"},{"key":"8499_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.4319","volume":"23","author":"JB Honeycutt","year":"2017","unstructured":"Honeycutt, J. B. et al. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 23, 638\u2013643 (2017).","journal-title":"Nat. Med."},{"key":"8499_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1172\/JCI80562","volume":"126","author":"JV Garcia","year":"2016","unstructured":"Garcia, J. V. In vivo platforms for analysis of HIV persistence and eradication.  J. Clin. Investig. 126, 424\u2013431 (2016).","journal-title":"J. Clin. Investig."},{"key":"8499_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1172\/JCI90025","volume":"127","author":"DP Gnanadhas","year":"2017","unstructured":"Gnanadhas, D. P. et al. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.  J. Clin. Investig. 127, 857\u2013873 (2017).","journal-title":"J. Clin. Investig."},{"key":"8499_CR40","doi-asserted-by":"publisher","first-page":"e1001228","DOI":"10.1371\/journal.ppat.1001228","volume":"6","author":"ME Curlin","year":"2010","unstructured":"Curlin, M. E. et al. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 6, e1001228 (2010).","journal-title":"PLoS Pathog."},{"key":"8499_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1586\/14760584.2014.951335","volume":"13","author":"RJ O\u2019Connell","year":"2014","unstructured":"O\u2019Connell, R. J., Kim, J. H. & Excler, J. L. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Rev. Vaccines 13, 1489\u20131500 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"8499_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01749-23","volume":"15","author":"E Lewitus","year":"2024","unstructured":"Lewitus, E. et al. HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s. mBio 15, e0174923 (2024).","journal-title":"mBio"},{"key":"8499_CR43","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8499_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19801-x","volume":"11","author":"MJ Siedner","year":"2020","unstructured":"Siedner, M. J. et al. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nat. Commun. 11, 5922 (2020).","journal-title":"Nat. Commun."},{"key":"8499_CR45","unstructured":"NIH, FDA-approved HIV medicines, National Institutes of Health. (2022)."},{"key":"8499_CR46","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","volume":"225","author":"SH Eshleman","year":"2022","unstructured":"Eshleman, S. H. et al. Characterization of Human Immunodeficiency Virus (HIV) infections in women who received injectable Cabotegravir or Tenofovir Disoproxil Fumarate\/Emtricitabine for HIV Prevention: HPTN 084. J. Infect. Dis. 225, 1741\u20131749 (2022).","journal-title":"J. Infect. Dis."},{"key":"8499_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"8499_CR48","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","volume":"226","author":"NA Margot","year":"2022","unstructured":"Margot, N. A. et al. Resistance analyses in highly treatment-experienced people with Human Immunodeficiency Virus (HIV) treated with the Novel Capsid HIV Inhibitor Lenacapavir. J. Infect. Dis. 226, 1985\u20131991 (2022).","journal-title":"J. Infect. Dis."},{"key":"8499_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.gene.2006.07.037","volume":"384","author":"C Briones","year":"2006","unstructured":"Briones, C. et al. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene 384, 129\u2013138 (2006).","journal-title":"Gene"},{"key":"8499_CR50","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3018(18)30177-2","volume":"5","author":"SC Inzaule","year":"2018","unstructured":"Inzaule, S. C. et al. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV 5, e638\u2013e646 (2018).","journal-title":"Lancet HIV"},{"key":"8499_CR51","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","volume":"5","author":"JA Johnson","year":"2008","unstructured":"Johnson, J. A. et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na\u00efve populations and associate with reduced treatment efficacy. PLoS Med. 5, e158 (2008).","journal-title":"PLoS Med."},{"key":"8499_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcv.2009.03.002","volume":"45","author":"M Balduin","year":"2009","unstructured":"Balduin, M. et al. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-na\u00efve patients and their impact on the virological failure. J. Clin. Virol. 45, 34\u201338 (2009).","journal-title":"J. Clin. Virol."},{"key":"8499_CR53","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1002\/jmv.26582","volume":"93","author":"D Tekin","year":"2021","unstructured":"Tekin, D. et al. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients. J. Med. Virol. 93, 3627\u20133633 (2021).","journal-title":"J. Med. Virol."},{"key":"8499_CR54","doi-asserted-by":"crossref","unstructured":"Li, M. et al. HIV Drug resistance mutations detection by next-generation sequencing during antiretroviral therapy interruption in China. Pathogens. 10, 1\u201313 (2021).","DOI":"10.3390\/pathogens10030264"},{"key":"8499_CR55","doi-asserted-by":"crossref","unstructured":"Tzou, P. L. et al. Comparison of an in vitro diagnostic next-generation sequencing assay with sanger sequencing for HIV-1 genotypic resistance testing. J. Clin. Microbiol. 56, 1\u201313 (2018).","DOI":"10.1128\/JCM.00105-18"},{"key":"8499_CR56","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. HIV-1 employs multiple mechanisms to resist Cas9\/Single Guide RNA targeting the viral primer binding site. J Virol. 92, 1\u201320 (2018).","DOI":"10.1128\/JVI.01135-18"},{"key":"8499_CR57","doi-asserted-by":"crossref","unstructured":"Binda, C. S. et al. CRISPR-Cas9 Dual-gRNA attack causes mutation, excision and inversion of the HIV-1 Proviral DNA. Viruses. 12, 1\u201312 (2020).","DOI":"10.3390\/v12030330"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08499-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:46:47Z","timestamp":1757260007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8499"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08499-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HEG co-founded Exavir Therapeutics, Inc., a company formed to develop LA ART. All other listed authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1077"}}